Pharma Pioneer

Medicenna Showcases Latest MDNA11 Monotherapy Outcomes from Phase 1/2 ABILITY-1 Trial at AACR's 2024 Annual Gathering

16 May 2024
2 min read

April 9, 2024 — Medicenna Therapeutics Corp. has reported positive interim results from its Phase 1/2 ABILITY-1 study of MDNA11, a long-acting interleukin-2 (IL-2) super-agonist, in patients with advanced solid tumors who have failed checkpoint inhibitor therapies. The study showed a 29% response rate and a 50% clinical benefit rate among the evaluated patients. Notably, two patients achieved a 100% reduction of target lesions, one with melanoma and another with pancreatic cancer

MDNA11 has demonstrated a favorable safety profile, with no dose-limiting toxicities or vascular leak syndrome reported. The treatment was well tolerated, and most treatment-related adverse events were of grade 1-2, resolving within 48 hours. The drug also exhibited potent immune effects, with sustained expansion of cytotoxic CD4+ T cells, CD8+ T cells, and NK cells, and minimal impact on immunosuppressive Tregs. 

The ABILITY-1 study includes a monotherapy dose escalation and an ongoing expansion phase. The monotherapy portion is enrolling patients with metastatic melanoma, non-melanoma skin cancers, and MSI-H/dMMR tumors. A combination dose escalation with pembrolizumab (Keytruda®) has also commenced. 

MDNA11 is a next-generation IL-2 variant engineered to activate immune effector cells with minimal stimulation of immunosuppressive Tregs. The drug is currently being evaluated as both a monotherapy and in combination with pembrolizumab. Medicenna is a clinical-stage immunotherapy company focused on developing novel Superkines and first-in-class Empowered Superkines to enhance the treatment of immunologically "cold" tumors. The company's lead product, MDNA11, has shown promising therapeutic activity and safety in patients with advanced solid tumors who have failed multiple prior lines of therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Promising Phase 1/2 Trial Data for Evorpacept Combined with Standard Treatment in Relapsed or Refractory B-cell NHL Patients
Pharma Pioneer
3 min read
Promising Phase 1/2 Trial Data for Evorpacept Combined with Standard Treatment in Relapsed or Refractory B-cell NHL Patients
16 May 2024
In a recent clinical trial, 20 patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) were administered a combination treatment of evorpacept, rituximab, and lenalidomide, commonly referred to as the "R2" regimen.
Read →
Vanqua Bio Commences Phase 1 Clinical Study with First Patient Administered VQ-101, a GCase Activator for GBA-PD and Associated Conditions
Pharma Pioneer
2 min read
Vanqua Bio Commences Phase 1 Clinical Study with First Patient Administered VQ-101, a GCase Activator for GBA-PD and Associated Conditions
16 May 2024
Vanqua Bio, a clinical-stage biopharmaceutical company, has dosed the first patient in a Phase 1 clinical trial for VQ-101, an oral, brain-penetrating small molecule allosteric activator of glucocerebrosidase (GCase).
Read →
Corvus Launches Randomized Phase 1 Clinical Trial for Soquelitinib in Treating Moderate to Severe Atopic Dermatitis
Pharma Pioneer
3 min read
Corvus Launches Randomized Phase 1 Clinical Trial for Soquelitinib in Treating Moderate to Severe Atopic Dermatitis
16 May 2024
Corvus Pharmaceuticals, a biopharmaceutical firm, has launched a Phase 1 clinical trial for soquelitinib, a selective ITK inhibitor, to treat moderate to severe atopic dermatitis.
Read →
Synthekine's STK-012 IL-2 Shows Promising Phase 1a/1b Results in Advanced Solid Tumor Treatment
Pharma Pioneer
2 min read
Synthekine's STK-012 IL-2 Shows Promising Phase 1a/1b Results in Advanced Solid Tumor Treatment
16 May 2024
Initial clinical trials for STK-012, an innovative engineered cytokine by Synthekine Inc., have shown promising results in treating advanced solid tumors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.